Steven C Cramer1,2, Jill See1, Brent Liu3, Matthew Edwardson4, Ximing Wang3, Shlomit Radom-Aizik5, Fadia Haddad5, Babak Shahbaba6, Steven L Wolf7, Alexander W Dromerick4, Carolee J Winstein8. 1. Neurology, 12222University of California, Irvine, CA, USA. 2. Dept. Neurology, University of California, Los Angeles; and California Rehabilitation Institute, Los Angeles, CA, USA. 3. 5116Image Processing and Informatics Lab, Dept. Biomedical Engineering, University of Southern California, Los Angeles, CA, USA. 4. Neurology, 8368Georgetown University, Washington, DC, USA. 5. 8788Pediatrics, University of California, Irvine, CA, USA. 6. 8788Statistics, University of California, Irvine, CA, USA. 7. 1371Dept. Rehabilitation Medicine, Division of Physical Therapy Education, Emory University; Atlanta VA Health Care System, Center for Visual and Neurocognitive Rehabilitation. 8. 5116Div. Biokinesiology and Physical Therapy and Dept. Neurology, University of Southern California, Los Angeles, CA, USA.
Abstract
OBJECTIVE: Patients show substantial differences in response to rehabilitation therapy after stroke. We hypothesized that specific genetic profiles might explain some of this variance and, secondarily, that genetic factors are related to cerebral atrophy post-stroke. METHODS: The phase 3 ICARE study examined response to motor rehabilitation therapies. In 216 ICARE enrollees, DNA was analyzed for presence of the BDNF val66met and the ApoE ε4 polymorphism. The relationship of polymorphism status to 12-month change in motor status (Wolf Motor Function Test, WMFT) was examined. Neuroimaging data were also evaluated (n=127). RESULTS: Subjects were 61±13 years old (mean±SD) and enrolled 43±22 days post-stroke; 19.7% were BDNF val66met carriers and 29.8% ApoE ε4 carriers. Carrier status for each polymorphism was not associated with WMFT, either at baseline or over 12 months of follow-up. Neuroimaging, acquired 5±11 days post-stroke, showed that BDNF val66met polymorphism carriers had a 1.34-greater degree of cerebral atrophy compared to non-carriers (P=.01). Post hoc analysis found that age of stroke onset was 4.6 years younger in subjects with the ApoE ε4 polymorphism (P=.02). CONCLUSION: Neither the val66met BDNF nor ApoE ε4 polymorphism explained inter-subject differences in response to rehabilitation therapy. The BDNF val66met polymorphism was associated with cerebral atrophy at baseline, echoing findings in healthy subjects, and suggesting an endophenotype. The ApoE ε4 polymorphism was associated with younger age at stroke onset, echoing findings in Alzheimer's disease and suggesting a common biology. Genetic associations provide insights useful to understanding the biology of outcomes after stroke.
OBJECTIVE: Patients show substantial differences in response to rehabilitation therapy after stroke. We hypothesized that specific genetic profiles might explain some of this variance and, secondarily, that genetic factors are related to cerebral atrophy post-stroke. METHODS: The phase 3 ICARE study examined response to motor rehabilitation therapies. In 216 ICARE enrollees, DNA was analyzed for presence of the BDNF val66met and the ApoE ε4 polymorphism. The relationship of polymorphism status to 12-month change in motor status (Wolf Motor Function Test, WMFT) was examined. Neuroimaging data were also evaluated (n=127). RESULTS: Subjects were 61±13 years old (mean±SD) and enrolled 43±22 days post-stroke; 19.7% were BDNF val66met carriers and 29.8% ApoE ε4 carriers. Carrier status for each polymorphism was not associated with WMFT, either at baseline or over 12 months of follow-up. Neuroimaging, acquired 5±11 days post-stroke, showed that BDNF val66met polymorphism carriers had a 1.34-greater degree of cerebral atrophy compared to non-carriers (P=.01). Post hoc analysis found that age of stroke onset was 4.6 years younger in subjects with the ApoE ε4 polymorphism (P=.02). CONCLUSION: Neither the val66met BDNF nor ApoE ε4 polymorphism explained inter-subject differences in response to rehabilitation therapy. The BDNF val66met polymorphism was associated with cerebral atrophy at baseline, echoing findings in healthy subjects, and suggesting an endophenotype. The ApoE ε4 polymorphism was associated with younger age at stroke onset, echoing findings in Alzheimer's disease and suggesting a common biology. Genetic associations provide insights useful to understanding the biology of outcomes after stroke.
Authors: Katherine Reiter; Kristy A Nielson; Sally Durgerian; John L Woodard; J Carson Smith; Michael Seidenberg; Dana A Kelly; Stephen M Rao Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Roberto Toro; Marie Chupin; Line Garnero; Gabriel Leonard; Michel Perron; Bruce Pike; Alain Pitiot; Louis Richer; Suzanne Veillette; Zdenka Pausova; Tomás Paus Journal: Brain Struct Funct Date: 2009-02-10 Impact factor: 3.270
Authors: Robyn A Honea; Carlos Cruchaga; Rodrigo D Perea; Andrew J Saykin; Jeffrey M Burns; Daniel R Weinberger; Alison M Goate Journal: PLoS One Date: 2013-09-26 Impact factor: 3.240
Authors: Kewei Chen; Eric M Reiman; Gene E Alexander; Richard J Caselli; Richard Gerkin; Daniel Bandy; Alisa Domb; David Osborne; Nick Fox; William R Crum; Ann M Saunders; John Hardy Journal: Am J Psychiatry Date: 2007-06 Impact factor: 18.112